Article Details

AstraZeneca's already dominant Lynparza lines up for early breast cancer with new trial win

Retrieved on: 2021-02-17 15:33:45

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca's already dominant Lynparza lines up for early breast cancer with new trial win. View article details on hiswai:

Excerpt

AstraZeneca said a phase 3 trial has found Lynparza worked as an adjuvant therapy in BRCA-mutated, high-risk, HER2-negative early breast cancer.

Article found on: www.fiercepharma.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up